A5036487478- Malaria Research and Control
- Computational Drug Discovery Methods
- Mosquito-borne diseases and control
- Drug-Induced Hepatotoxicity and Protection
- COVID-19 epidemiological studies
- SARS-CoV-2 detection and testing
- SARS-CoV-2 and COVID-19 Research
- Travel-related health issues
- Research on Leishmaniasis Studies
- Vaccine Coverage and Hesitancy
- COVID-19 Pandemic Impacts
- Influenza Virus Research Studies
- Viral Infections and Outbreaks Research
- Viral Infections and Vectors
- HIV/AIDS drug development and treatment
- Venomous Animal Envenomation and Studies
- Data-Driven Disease Surveillance
- Respiratory viral infections research
- Drug Transport and Resistance Mechanisms
- COVID-19 impact on air quality
- Parasites and Host Interactions
- Global Security and Public Health
- Pharmaceutical Economics and Policy
Centers for Disease Control and Prevention
2017-2024
U.S. President's Malaria Initiative
2019-2024
CDC Foundation
2022
Division of Parasitic Diseases and Malaria
2019-2022
National Application Center for Pharmaceutical Research
2021
Center for Global Health
2019-2021
Georgia State University
2021
Institut Pasteur de Madagascar
2021
Centers for Disease Control and Prevention
2020
Emory University
2014
An estimated 30 million passengers are transported on 272 cruise ships worldwide each year* (1). Cruise bring diverse populations into proximity for many days, facilitating transmission of respiratory illness (2). SARS-CoV-2, the virus that causes coronavirus disease (COVID-19) was first identified in Wuhan, China, December 2019 and has since spread to at least 187 countries territories. Widespread COVID-19 been reported as well (3). Passengers certain ship voyages might be aged ≥65 years,...
Abstract Background The World Health Organization recommends regularly assessing the efficacy of artemisinin-based combination therapy (ACT), which is a critical tool in fight against malaria. This study evaluated two combinations recommended to treat uncomplicated Plasmodium falciparum malaria Burkina Faso three sites: Niangoloko, Nanoro, and Gourcy. Methods was two-arm randomized control trial artemether-lumefantrine (AL) dihydroartemisinin-piperaquine (DP). Children aged 6–59 months old...
Therapeutic efficacy studies (TESs) and detection of molecular markers drug resistance are recommended by the World Health Organization (WHO) to monitor artemisinin-based combination therapy (ACT). This study assessed trends artemisinin and/or reduced susceptibility lumefantrine using samples collected in TES conducted Mainland Tanzania from 2016 2021.
In Uganda, artemether-lumefantrine (AL) is first-line therapy and dihydroartemisinin-piperaquine (DP) second-line for the treatment of uncomplicated malaria. This study evaluated efficacy safety AL DP in management falciparum malaria measured prevalence molecular markers resistance three sentinel sites Uganda from 2018 to 2019.This was a randomized, open-label, phase IV clinical trial. Children aged 6 months 10 years with were randomly assigned or followed 28 42 days, respectively....
Abstract We enrolled arriving international air travelers in a severe acute respiratory syndrome coronavirus 2 genomic surveillance program. used molecular testing of pooled nasal swabs and sequenced positive samples for sublineage. Traveler-based provided early-warning variant detection, reporting the first US Omicron BA.2 BA.3 North America.
Abstract Background The Diamond Princess cruise ship was the site of a large outbreak coronavirus disease 2019 (COVID-19). Of 437 Americans and their travel companions on ship, 114 (26%) tested positive for severe acute respiratory syndrome 2 (SARS-CoV-2). Methods We interviewed 229 American passengers crew after disembarkation following ship-based quarantine to identify risk factors infection characterize transmission onboard ship. Results attack rate in single-person cabins or without...
Routine assessment of the efficacy artemisinin-based combination therapies (ACTs) is critical for early detection antimalarial resistance. We evaluated ACTs recommended treatment uncomplicated malaria in five sites Democratic Republic Congo (DRC): artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ), and dihydroartemisinin-piperaquine (DP). Children aged 6-59 months with confirmed Plasmodium falciparum were treated one three monitored. The primary endpoints uncorrected polymerase...
Abstract The Global Health Security Agenda (GHSA), a partnership of nations, international organizations, and civil society, was launched in 2014 with mission to build countries’ capacities respond infectious disease threats foster global compliance the International Regulations (IHR 2005). US Centers for Disease Control Prevention (CDC) assists partner nations improve IHR 2005 achieve GHSA targets. To assess progress through these CDC-supported efforts, we analyzed country activity reports...
The spread of drug resistance to antimalarial treatments poses a serious public health risk globally. To combat this risk, molecular surveillance is imperative. We report the prevalence mutations in Plasmodium falciparum kelch 13 propeller domain associated with partial artemisinin resistance, which we determined by using Sanger sequencing samples from patients enrolled therapeutic efficacy studies 9 sub-Saharan countries during 2014-2018. Of 2,865 successfully sequenced before treatment...
The World Health Organization recommends the use of artemisinin-based combination therapy (ACT) to treat uncomplicated malaria for control across world. There are several types ACT used malaria-endemic countries, yet there is little information about preferences and adherence practices regarding different ACT. objective this study was evaluate levels two ACT, artemether–lumefantrine (AL) artesunate + amodiaquine (ASAQ), treatment among prescribers patients in Guinea 2016. included a review...
Artemisinin-based combination therapy (ACT) has been the recommended first-line treatment for uncomplicated malaria in Mozambique since 2006, with artemether-lumefantrine (AL) and amodiaquine-artesunate (AS-AQ) as first choice. To assess efficacy of currently used ACT, an vivo therapeutic study was conducted.The conducted four sentinel sites: Montepuez, Moatize, Mopeia Massinga. Patients between 6 59 months old Plasmodium falciparum (2000-200,000 parasites/µl) were enrolled February...
Abstract Background Routine monitoring of anti-malarial drugs is recommended for early detection drug resistance and to inform national malaria treatment guidelines. In Ethiopia, the guidelines employ a species-specific approach. Artemether-lumefantrine (AL) chloroquine (CQ) are first-line schizonticidal treatments Plasmodium falciparum vivax , respectively. The National Malaria Control Elimination Programme in Ethiopia considering dihydroartemisinin-piperaquine (DHA/PPQ) as an alternative...
Abstract Background Since 2005, artemisinin-based combination therapy (ACT) has been recommended to treat uncomplicated falciparum malaria in Madagascar. Artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) are the first- second-line treatments, respectively. A therapeutic efficacy study was conducted assess ACT molecular markers of anti-malarial resistance. Methods Children aged six months 14 years with a parasitaemia 1000–100,000 parasites/µl determined by microscopy were...
Abstract Background The current first-line treatments for uncomplicated malaria recommended by the National Malaria Control Programme in Mali are artemether–lumefantrine (AL) and artesunate–amodiaquine (ASAQ). From 2015 to 2016, an vivo study was carried out assess clinical parasitological responses AL ASAQ Sélingué, Mali. Methods Children between 6 59 months of age with Plasmodium falciparum infection 2000–200,000 asexual parasites/μL blood were enrolled, randomly assigned either or ASAQ,...
We surveyed U.S. immunization program managers (IPMs) as part of a project to improve public health preparedness against future emergencies by leveraging the system. examined policy and Immunization Information System (IIS) functionality changes result Haemophilus influenzae type B (Hib) vaccine shortage pandemic influenza A(H1N1) (pH1N1). Evaluating in functionalities policies following emergency response situations will assist planning for vaccine-related emergencies.We administered three...
In 2005, artemether-lumefantrine (AL), an artemisinin-based combination therapy, was introduced as the first-line treatment of uncomplicated Plasmodium falciparum malaria in Benin. Per World Health Organization recommendations to monitor efficacy antimalarial treatment, we conducted a therapeutic study with AL for P. Bohicon and Kandi, Benin, from 2018 2019. Febrile patients aged 6 59 months confirmed monoinfection received supervised doses 3 days. We monitored clinically parasitologically...
We enrolled arriving international air travelers in SARS-CoV-2 genomic surveillance, using molecular testing of pooled nasal swabs, and sequencing positive samples for viral lineage. Traveler-based surveillance provided early warning variant detection; we reported the first U.S. Omicron BA.2 BA.3 North America, weeks before next detection.
Abstract Background Therapeutic efficacy studies (TESs) and detection of molecular markers drug resistance are recommended by the World Health Organization (WHO) to monitor artemis inin combination therapy (ACT). This study assessed trends and/or reduced susceptibility lumefantrine using samples collected in TES conducted Mainland Tanzania from 2016 2021. Methods A total 2,015 were during artemether-lumefantrine at eight sentinel sites (in Kigoma, Mbeya, Morogoro, Mtwara, Mwanza, Pwani,...
Article summary This study suggests that: 1) patients given AL infected with parasites carrying N86 were statistically more likely to experience a recurrent infection; 2) ASAQ 86Y infection. Background Plasmodium falciparum multidrug resistance transporter 1 ( Pfmdr1 ) gene mutations are associated altered response artemisinin-based combination therapies (ACTs), particularly those containing the partner drugs lumefantrine and amodiaquine (i.e., artemether-lumefantrine [AL]...